Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI.
about
Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quailTherapies for the bone in mucopolysaccharidosesLong-term amelioration of feline Mucopolysaccharidosis VI after AAV-mediated liver gene transferMucopolysaccharidosis VI.Therapies of mucopolysaccharidosis IVA (Morquio A syndrome).Enzyme replacement therapy for the mucopolysaccharide storage disorders.Newborn screening and diagnosis of mucopolysaccharidoses: application of tandem mass spectrometry.Production of MPS VII mouse (Gus(tm(hE540A x mE536A)Sly)) doubly tolerant to human and mouse beta-glucuronidaseMolecular Genetics and Metabolism Report Long-term follow-up of post hematopoietic stem cell transplantation for Hurler syndrome: clinical, biochemical, and pathological improvements.Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey.Electrocardiographic and other cardiac anomalies in beta-glucuronidase-null mice corrected by nonablative neonatal marrow transplantationMucopolysaccharidosis type VI in a Miniature Poodle-type dog caused by a deletion in the arylsulphatase B gene.Long-term galsulfase enzyme replacement therapy in Taiwanese mucopolysaccharidosis VI patients: A case seriesStructural, compositional, and biomechanical alterations of the lumbar spine in rats with mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome).Two mutations within a feline mucopolysaccharidosis type VI colony cause three different clinical phenotypes.Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI.Mucopolysaccharidosis type VI on enzyme replacement therapy since infancy: Six years follow-up of four children.Randomized controlled trial of Hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses.Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI: 10-Year follow up.Correction of murine mucopolysaccharidosis type IIIA central nervous system pathology by intracerebroventricular lentiviral-mediated gene delivery.Autologous transplantation of retrovirally transduced bone marrow or neonatal blood cells into cats can lead to long-term engraftment in the absence of myeloablation.Mucopolysaccharidosis Type VI in a Great Dane Caused by a Nonsense Mutation in the ARSB Gene.Enzyme replacement in murine mucopolysaccharidosis type VII: neuronal and glial response to beta-glucuronidase requires early initiation of enzyme replacement therapy.Intrathecal recombinant human 4-sulfatase reduces accumulation of glycosaminoglycans in dura of mucopolysaccharidosis VI cats.Mild feline mucopolysaccharidosis type VI. Identification of an N-acetylgalactosamine-4-sulfatase mutation causing instability and increased specific activity.Advantages of early replacement therapy for mucopolysaccharidosis type VI: echocardiographic follow-up of siblings
P2860
Q24564823-52EF34CD-E17D-44A3-9150-E712BDD7EA7BQ26852308-BCD7A0CF-BA51-4B2C-990D-3D1DE92AE04CQ30498316-378FEC4E-20BC-45CA-B0DE-7892EFFC2C4FQ33863356-04084B86-9323-42C7-8370-2BC96E61527AQ34545883-F94DEF12-5F86-436B-8EC7-657456012648Q34628680-63AF5063-CAEA-4966-95E5-1F1F8AC1A2C2Q35000585-35BCA5DC-1322-4A9D-8390-8D0BF0FF4C7DQ35032587-CC70E38B-AD8B-4A47-961B-0F215B5149FEQ35104361-A26FCC67-E87C-4048-8F42-53037F8C0B15Q35128899-4F13B133-8DE9-4B44-83E0-8077D3A000F0Q35735485-593997A5-65D4-4AE5-9F8B-5B1C9C4EA890Q36108146-7C161E51-EB7B-4907-B091-7D9C7852CC0AQ36806851-96E38E3F-D4A2-4B0C-A382-B4A65A069D73Q36821152-2DFCDF07-AA5C-474C-90B0-B1C8D737C8C3Q37376943-7BFE4E3D-C955-4708-B439-C62B0BE4401CQ37686034-EC3AFC1E-7E7D-4FDF-8AC2-687A77B546F7Q41773483-BDF7DC8B-C3FF-4EA9-9E9E-3E4DC2F42DD8Q42059101-540F0FCD-2FA8-428A-9503-320944D9AF44Q42128578-4C1D9140-49AE-47F4-8B33-0DBEAD81C94DQ42180849-A7B4BA88-4B90-402C-906D-185966A5D760Q45858480-B62D7E6A-8A97-4A9E-8EA1-6811882D9981Q47705730-695D8180-E53D-47C1-AF1F-657BEBA92BE9Q48187605-704390AC-F3F5-48C4-BFB4-28CDA7120C79Q53674199-262D164C-C259-43FA-AF6F-9E07E54BF248Q54709909-D7BACF30-0FA5-4F7F-A224-7C58C33D9C8DQ57234995-062A9E0E-A53B-4AFF-A036-302DDF57AF27
P2860
Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 1997
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI.
@en
Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI.
@nl
type
label
Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI.
@en
Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI.
@nl
prefLabel
Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI.
@en
Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI.
@nl
P2093
P2860
P356
P1476
Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI.
@en
P2093
A C Crawley
J J Hopwood
K H Niedzielski
P2860
P304
P356
10.1172/JCI119208
P407
P577
1997-02-01T00:00:00Z